However, subgroup analysis suggested benefit in those with an average SBP approximately >140 mm Hg (and a CVD risk of 6.5% during the 5.6 years of follow- We acknowledge the importance of excluding white coat hypertension before initiating pharmacological therapy in hypertensive patients with low ASCVD risk. This may be accomplished (as described in Section 4) by HBPM or ABPM as appropriate. 8.1.3. Follow-Up After Initial BP Evaluation Recommendations for Follow-Up After Initial BP Evaluation References that support recommendations are summarized in Online Data Supplement 24. COR LOE Recommendations I B-R 1. Adults with an elevated BP or stage 1 hypertension who have an estimated 10- year ASCVD risk less than 10% should be managed with nonpharmacological therapy and have a repeat BP evaluation within 3 to I B-R 2. Adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of 10% or higher should be managed initially with a combination of nonpharmacological and antihypertensive drug therapy and have a repeat BP evaluation in 1 month.S8.1.3-1,S8.1.3-2 I B-R 3. Adults with stage 2 hypertension should be evaluated by or referred to a primary care provider within 1 month of the initial diagnosis, have a combination of nonpharmacological and antihypertensive drug therapy (with 2 agents of different classes) initiated, and have a repeat BP I B-R 4. For adults with a very high average BP (eg, SBP 180 mm Hg or DBP 110 mm Hg), evaluation followed by prompt antihypertensive drug treatment is recommended.S8.1.3-1,S8.1.3-2 IIa C-EO 5. For adults with a normal BP, repeat evaluation every year is reasonable. Synopsis An important component of BP management in hypertensive patients is follow-up. 